Spyre Therapeutics (SYRE) Change in Account Payables (2015 - 2026)

Spyre Therapeutics has reported Change in Account Payables for 12 years, with the latest figure at $36000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables fell 98.81% year-over-year to $36000.0; the trailing twelve-month figure through Mar 2026 stood at -$3.6 million (down 713.38% YoY), and the FY2025 full-year result was -$589000.0, down 156.09% from the prior year.
• Change in Account Payables for Q1 2026 stood at $36000.0, up from -$7.4 million in the prior quarter.
• The five-year high for Change in Account Payables was $7.4 million in Q3 2025, with the low at -$7.4 million in Q4 2025.
• Historically, Change in Account Payables has averaged -$37666.7 across 5 years, with a median of $125000.0 in 2024.
• Annual changes were most pronounced in 2022 — Change in Account Payables jumped 503.58% — and 2025, when it tumbled 2976.0%.
• Spyre Therapeutics' Change in Account Payables stood at $1.4 million in 2022, then jumped by 72.56% to $2.3 million in 2023, then sank by 292.8% to -$4.5 million in 2024, then tumbled by 64.07% to -$7.4 million in 2025, then surged by 100.49% to $36000.0 in 2026.
• The last three Change in Account Payables figures came in at $36000.0 (Q1 2026), -$7.4 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.